Jeffrey William Henderson, Director of Halozyme Therapeutics HALO, has filed 1 purchase and 17 sales on the open market. The latest trade was on 05/05.

JH

JH

Jeffrey William Henderson

Director

Company

Halozyme Therapeutics HALO

First filing

23/01/26

Trades

46 trades

Buys / sales

1 / 17

12-month net buying

No record

Last trade

05/05

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Halozyme TherapeuticsHALO	Open-market sale10b5-1 plan	25/04/28	25/04/28	4,497 sh2 trades	$60.37avg.	$271,480.98	−13.6%
Halozyme TherapeuticsHALO	Open-market sale10b5-1 plan	25/04/01	25/04/01	503 sh	$64.05	$32,217.15	−1.5%
Halozyme TherapeuticsHALO	Open-market sale10b5-1 plan	25/03/03	25/03/03	5,000 sh2 trades	$58.69avg.	$293,463.95	−12.9%
Becton DickinsonBDX	Open-market buy	25/02/10	25/02/10	1,500 sh	$233.62	$350,430	+23.0%
Halozyme TherapeuticsHALO	Open-market sale10b5-1 plan	25/02/03	25/02/04	5,000 sh2 trades	$56.31avg.	$281,533	−11.5%
Halozyme TherapeuticsHALO	Open-market sale10b5-1 plan	25/01/06	25/01/07	10,000 sh	$50.01	$500,100	−18.7%
Kyntra BioKYNB	Open-market sale10b5-1 plan	23/09/01	23/09/06	2,000 sh	$1.03	$2,060	−6.5%
Kyntra BioKYNB	Open-market sale10b5-1 plan	23/08/04	23/08/08	2,000 sh	$1.91	$3,820	−6.1%
Kyntra BioKYNB	Open-market sale10b5-1 plan	23/07/11	23/07/13	2,000 sh	$2.69	$5,380	−5.7%
Kyntra BioKYNB	Open-market sale10b5-1 plan	23/06/08	23/06/09	7,000 sh2 trades	$17.46avg.	$122,185.08	−16.7%
Halozyme TherapeuticsHALO	Open-market sale	23/02/28–23/03/01	23/03/01	20,000 sh2 trades	$48.11avg.	$962,200	−33.9%
QualcommQCOM	Open-market sale	23/02/22–23/02/23	23/02/24	5,000 sh2 trades	$124.12avg.	$620,600	−70.4%